The AfroCAB will promote the advancement of the issues affecting people living with HIV in Africa.

Yet the U.S., long a leader in TB elimination efforts, is in jeopardy of losing ground in the struggle to get to zero.

Three recent studies have significantly advanced TB drug development.

The toolkit is designed to help countries develop or strengthen their national response to drug-resistant tuberculosis.

The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.

Delamanid, an investigational drug to combat tuberculosis, improves outcomes and reduces mortality among patients with the multidrug resistant form of the disease.

South Africa’s Medicines Control Council will continue to deny compassionate access to bedaquiline that for many drug resistant patients is their last hope.

Global Fund supported programs have since 2002 detected and treated 9.3 million new smear-positive cases of tuberculosis.

Eastern Europe and Central Asian countries will not have the funds required to aggressively tackle their TB and HIV epidemics.

The question the tuberculosis community is anxiously posing is whether, in addition to existing drugs, the most promising compounds in the development pipeline are as effective as preliminary studies suggested.